Why is Bal Pharma falling/rising?

As of 01-Sep, Bal Pharma Ltd's stock price is currently at 89.00, reflecting an increase of 1.0, or 1.14%. The stock has shown a positive trend recently, gaining 3.61% over the last two days and outperforming its sector by 1.17%. However, despite this short-term gain, the stock has experienced a significant decline of 39.19% over the past year, with profits falling by 5.4%. The company has a Return on Capital Employed (ROCE) of 10.8, which indicates an attractive valuation compared to its peers, but it is trading at a discount relative to historical averages. The stock's performance is further complicated by a high Debt to EBITDA ratio of 5.12 times and negative results reported for the last three consecutive quarters.
In the broader market context, Bal Pharma's recent 1-week return of +2.19% stands in stark contrast to the Sensex, which has declined by 1.56% during the same period. This suggests that while the stock is experiencing a short-term recovery, it has underperformed significantly over longer periods, including a 27.20% decline year-to-date compared to a 2.85% increase in the Sensex. The stock's liquidity is adequate for trading, but a notable drop in delivery volume indicates falling investor participation, which could hinder sustained upward momentum. Overall, while there are some positive indicators in the short term, the long-term fundamentals remain weak, contributing to a cautious outlook for the stock.